SHTPY (Schott Pharma AG KGaA) Quality Rank


SHTPY Schott Pharma AG & CO KGaA SHTPY
64 GF Score
Price $4.37
GF Value $7.02
! 2 Warning Signs
View Full Analysis

What is Schott Pharma AG KGaA Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Schott Pharma AG KGaA Quality Rank Related Terms

SHTPY
64GF Score
Schott Pharma AG & CO KGaA SHTPY
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?

Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued. The current stock price of $4.37 is trading 37.7% below its estimated GF Value™ of $7.02.

Key valuation signals for SHTPY:

  • Quality Rank:
  • GF Value™: $7.02 vs. price of $4.37 (37.7% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Schott Pharma AG KGaA Business Description

Address Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score

Get the complete analysis for SHTPY

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.37
Price
$7.02
GF Value